Gene therapy in systemic lupus erythematosus

Lupus

Volumn 13, Issue 5, 2004, Pages 353-358

  Kyttaris, V C ^a,b   Juang, Y T ^a   Tsokos, George C ^a,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c WRAIR   (United States)

Author keywords

All therapy; Cytokines; Gene therapy; Genetics; SLE

Indexed keywords

CYTOKINE;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL BASED GENE THERAPY; CELL INTERACTION; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFICACY; GENE CONSTRUCT; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC MODIFIED B CELL; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICALLY MODIFIED DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

CHROMOSOME MAPPING; CYTOKINES; GENE THERAPY; HUMANS; LOD SCORE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 2942716916     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu1026oa     Document Type: Article

References (42)

1. Tsokos GC, Boumpas DT. Systemic lupus erythematosus. In Theofilopoulos A, Bona C eds. Molecular pathology of autoimmunity. Gordon and Breach, Harwood Academic Publishers, 2001: 255-281.
2. Kammer GM, Tsokos GC. Molecular aberrations in human lupus. Mol Med Today 2000; 6: 418-424.
3. Mackay I, Rosen F. Advances in immunology: complement, second of two parts. N Engl J Med 2001; 344: 1140-1144.
4. Arnett FC, Reveille JD, Wilson RW et al. Systemic lupus erythematosus: current state of the genetic hypothesis. Semin Arthritis Rheum 1984; 14: 24-35.
5. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11: 352-356.
6. Deapen D, Escalante A, Weinrib L et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-318.
7. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003; 24: 595-602.
8. Kyttaris VC, Tsokos GC. Uncovering the genetics of systemic lupus erythematosus. Am J Pharmacso 2003; 3: 193-202.
9. Karassa FB, Bijl M, Davies KA et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48: 1930-1938.
10. Salmon JE, Millard S, Schachter LA et al. Fc gamma RIIA alleles are heritable risk for SLE nephritis in African Americans. J Clin Invest 1996; 97: 1348-1354.
11. Edberg JC, Langfeld CD, Wu J et al. Genetic linkage and association of Fcγr Receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2132-2140.
12. Salmon JE, Pricop L. Human receptors of immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 2001; 44: 739-750.
13. Browness P, Davies KA, Norsworthy PJ et al. Hereditary C1q deficiency and systemic lupus erythematosus. QMJ 1994; 87: 455-464.
14. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324.
15. Tsao BP, Cantor RM, Grossman M et al. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 1999; 103: 1135-1140.
16. Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genetics 2002; 32: 666-669.
17. Evans CH, Ghivizzani SC, Oligino TJ, Robbins PD. Gene therapy for autoimmune disorders. J Clin Inv 2000; 20: 334-346.
18. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
19. Prud'homme GJ, Lawson BR, Theofilopoulos AN. Anticytokine gene therapy of autoimmune diseases. Exp Opin Biol Ther 2001; 1: 359-373.
20. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy in lupus. Gene Ther 2003; 10: 861-874.
21. Prud'homme GJ, Kono DH, Theofilopoulos AN. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Molec Immunol 1995; 32: 495-503.
22. Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999; 6: 771-777.
23. Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 fusion protein. J Gene Med 1999; 1: 415-423.
24. Lawson BR, Prud'homme GJ, Chang Y et al. Treatment of murine lupus with cDNA encoding IFN-[gamma]R/Fc. J Clin Inv 2000; 106: 207-215.
25. Raz E, Dudler J, Lotz M et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-292.
26. Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus 1999; 8: 29-38.
27. Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/ vaccinia recombinant virus. Nature 1990; 346: 271-274.
28. Huang FP, Feng GJ, Lindop G, Strott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med 1996; 183: 1447-1459.
29. Hagiwara E, Okubo T, Aoki I et al. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Cytokine 2000; 12: 1035-1041.
30. Yasuda T, Yoshimoto T, Tsubura A, Matsuzawa A. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice. Cell Immunol 2001; 210: 77-86.
31. Takiguchi M, Murakami M, Nakagawa I, Salto I, Hashimoto A, Uede T. CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 2000; 66: 991-1001.
32. Wong HK, Kammer GM, Dennis G, Tsokos GC. Abnormal NF-kB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 1999; 163: 1682-1689.
33. Hemdon TM, Juang Y-T, Solomou EE, Rothwell SW, Gourley MF, Tsokos GC. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin Immunol 2002; 103: 145-153.
34. Solomou EE, Juang Y-T, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001; 166: 4216-4222.
35. Tenbrock K, Juang Y-T, Gourley MF, Nambiar MP, Tsokos GC. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunol 2002; 169: 4147-4152.
36. Kammer GM, Perl A, Richardson BC, Tsokos GC. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1139-1154.
37. Nambiar MP, Fisher CU, Warke VG et al. Reconstitution of deficient T cell receptor æ chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1948-1955.
38. Liu Z, Xu X, Hsu HC et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Inv 2003; 112: 1332-1341.
39. El Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 2000; 165: 5631-5636.
40. Zambidis ET, Barth RK, Scott DW. Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J Immunol 1997; 158: 2174-2182.
41. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 2000; 106: 245-252.
42. Melo ME, Qian J, El Amine M et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002; 168: 4788-4795.